Email Alert RSS
Volume 13 Issue 4
Jul.  2022
Turn off MathJax
Article Contents
Abstract
References
Related Articles
WANG Shijun, LI Yingjie, WEN Jin. Advances in Urinary Tumor Markers of Prostate Cancer[J]. Medical Journal of Peking Union Medical College Hospital, 2022, 13(4): 652-657. DOI: 10.12290/xhyxzz.2021-0774
Citation: WANG Shijun, LI Yingjie, WEN Jin. Advances in Urinary Tumor Markers of Prostate Cancer[J]. Medical Journal of Peking Union Medical College Hospital, 2022, 13(4): 652-657. DOI: 10.12290/xhyxzz.2021-0774
shu

Advances in Urinary Tumor Markers of Prostate Cancer

  • Department of Urology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100730, China

Funds: 

Non-profit Central Research Institute Fund of Chinese Academy of Medical Sciences 2019XK320027

Project Management Fund of Foreign Cultural and Educational Experts G20190001645

More Information
  • Corresponding author:

    WEN Jin, E-mail: wjpumch@163.com

  • Received Date: December 04, 2021
  • Accepted Date: December 28, 2021
  • Available Online: April 05, 2022
  • Issue Publish Date: July 29, 2022
    Graphical Abstract
    • Abstract
  • Prostate cancer (PCa) is currently the second most common cancer in men worldwide.The current gold standard for diagnosing PCa relies on ultrasound-guided systematic core needle biopsy after detection changes in a digital rectal examination and elevated prostate-specific antigen(PSA) level in the blood serum. Yet, serum PSA cannot reliably discriminate between benign pathologies and clinically significant forms of PCa. A common problem caused by the low specificity of this marker is over diagnosis, which leads to unnecessary biopsies and over treatment. This may be associated with various treatment complications (such as bleeding or infection) and generate unnecessary costs. Therefore, there is an urgent need for more specific and predictive biomarkers to effectively discriminate between aggressive and nonaggressive tumors and to avoid unnecessary prostate biopsies. Biomarkers derived from prostate cancer cells are released into prostatic fluids and then into urine. Urine after manipulation of the prostate is enriched with PCa biomarkers, including prostate cancer cells, DNAs, RNAs, proteins and other small molecules. In recent years, several non-invasive, cost-effective, high-accuracy urinary diagnostic biomarkers such as PSA, PCA3, MALAT1 and microRNA have been developed. This article reviews the biomarkers for the non-invasive testing of PCa in urine.
    • FullText(HTML)
    • References (46)
  • [1]
    Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries[J]. CA Cancer J Clin, 2021, 71: 209-249. DOI: 10.3322/caac.21660
    [2]
    Allemani C, Matsuda T, Di Carlo V, et al. Global surveillance of trends in cancer survival 2000-14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries[J]. Lancet, 2018, 391: 1023-1075. DOI: 10.1016/S0140-6736(17)33326-3
    [3]
    Siegel RL, Miller KD, Fuchs HE, et al. Cancer Statistics, 2021[J]. CA Cancer J Clin, 2021, 71: 7-33. DOI: 10.3322/caac.21654
    [4]
    Wong MC, Goggins WB, Wang HH, et al. Global Incidence and Mortality for Prostate Cancer: Analysis of Temporal Patterns and Trends in 36 Countries[J]. Eur Urol, 2016, 70: 862-874. DOI: 10.1016/j.eururo.2016.05.043
    [5]
    Draisma G, Etzioni R, Tsodikov A, et al. Lead Time and Overdiagnosis in Prostate-Specific Antigen Screening: Importance of Methods and Context[J]. J Natl Cancer Inst, 2009, 101: 374-383. DOI: 10.1093/jnci/djp001
    [6]
    Salagierski M, Schalken JA. Molecular diagnosis of prostate cancer: PCA3 and TMPRSS2: ERG gene fusion[J]. J Urol, 2012, 187: 795-801. DOI: 10.1016/j.juro.2011.10.133
    [7]
    Fenton JJ, Weyrich MS, Durbin S, et al. Prostate-Specific Antigen-Based Screening for Prostate Cancer: Evidence Report and Systematic Review for the US Preventive Services Task Force[J]. JAMA, 2018, 319: 1914-1931. DOI: 10.1001/jama.2018.3712
    [8]
    Eskra JN, Rabizadeh D, Pavlovich CP, et al. Approaches to urinary detection of prostate cancer[J]. Prostate Cancer Prostatic Dis, 2019, 22: 362-381. DOI: 10.1038/s41391-019-0127-4
    [9]
    Bussemakers MJ, Van Bokhoven A, Verhaegh GW, et al. DD3: a new prostate-specific gene, highly overexpressed in prostate cancer[J]. Cancer Res, 1999, 59: 5975-5979.
    [10]
    Truong M, Yang B, Jarrard DF. Toward the detection of prostate cancer in urine: a critical analysis[J]. J Urol, 2013, 189: 422-429. DOI: 10.1016/j.juro.2012.04.143
    [11]
    Marks LS, Fradet Y, Deras IL, et al. PCA3 molecular urine assay for prostate cancer in men undergoing repeat biopsy[J]. Urology, 2007, 69: 532-535. DOI: 10.1016/j.urology.2006.12.014
    [12]
    Ploussard G, de la Taille A. The role of prostate cancer antigen 3 (PCA3) in prostate cancer detection[J]. Expert Rev Anticancer Ther, 2018, 18: 1013-1020. DOI: 10.1080/14737140.2018.1502086
    [13]
    Lee D, Shim SR, Ahn ST, et al. Diagnostic Performance of the Prostate Cancer Antigen 3 Test in Prostate Cancer: Systematic Review and Meta-analysis[J]. Clin Genitourin Cancer, 2020, 18: 402-408. e5. DOI: 10.1016/j.clgc.2020.03.005
    [14]
    Salciccia S, Capriotti AL, Laganà A, et al. Biomarkers in Prostate Cancer Diagnosis: From Current Knowledge to the Role of Metabolomics and Exosomes[J]. Int J Mol Sci, 2021, 22: 4367. DOI: 10.3390/ijms22094367
    [15]
    Tomlins SA, Rhodes DR, Perner S, et al. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer[J]. Science, 2005, 310: 644-648. DOI: 10.1126/science.1117679
    [16]
    Hessels D, Smit FP, Verhaegh GW, et al. Detection of TMPRSS2-ERG fusion transcripts and prostate cancer antigen 3 in urinary sediments may improve diagnosis of prostate cancer[J]. Clin Cancer Res, 2007, 13: 5103-5108. DOI: 10.1158/1078-0432.CCR-07-0700
    [17]
    Leyten GH, Hessels D, Jannink SA, et al. Prospective multicentre evaluation of PCA3 and TMPRSS2-ERG gene fusions as diagnostic and prognostic urinary biomarkers for prostate cancer[J]. Eur Urol, 2014, 65: 534-542. DOI: 10.1016/j.eururo.2012.11.014
    [18]
    Tomlins SA, Day JR, Lonigro RJ, et al. Urine TMPRSS2: ERG Plus PCA3 for Individualized Prostate Cancer Risk Assessment[J]. Eur Urol, 2016, 70: 45-53. DOI: 10.1016/j.eururo.2015.04.039
    [19]
    Sanda MG, Feng Z, Howard DH, et al. Association Between Combined TMPRSS2: ERG and PCA3 RNA Urinary Testing and Detection of Aggressive Prostate Cancer[J]. JAMA Oncol, 2017, 3: 1085-1093. DOI: 10.1001/jamaoncol.2017.0177
    [20]
    Tosoian JJ, Trock BJ, Morgan TM, et al. Use of the MyProstateScore Test to Rule Out Clinically Significant Cancer: Validation of a Straightforward Clinical Testing Approach[J]. J Urol, 2021, 205: 732-739. DOI: 10.1097/JU.0000000000001430
    [21]
    Ji P, Diederichs S, Wang W, et al. MALAT-1, a novel noncoding RNA, and thymosin beta4 predict metastasis and survival in early-stage non-small cell lung cancer[J]. Oncogene, 2003, 22: 8031-8041. DOI: 10.1038/sj.onc.1206928
    [22]
    Luan W, Li L, Shi Y, et al. Long non-coding RNA MALAT1 acts as a competing endogenous RNA to promote malignant melanoma growth and metastasis by sponging miR-22[J]. Oncotarget, 2016, 7: 63901-63912. DOI: 10.18632/oncotarget.11564
    [23]
    Ren S, Peng Z, Mao JH, et al. RNA-seq analysis of prostate cancer in the Chinese population identifies recurrent gene fusions, cancer-associated long noncoding RNAs and aberrant alternative splicings[J]. Cell Res, 2012, 22: 806-821. DOI: 10.1038/cr.2012.30
    [24]
    Wang F, Ren S, Chen R, et al. Development and prospec-tive multicenter evaluation of the long noncoding RNA MALAT-1 as a diagnostic urinary biomarker for prostate cancer[J]. Oncotarget, 2014, 5: 11091-11102. DOI: 10.18632/oncotarget.2691
    [25]
    Goyal B, Yadav SRM, Awasthee N, et al. Diagnostic, prognostic, and therapeutic significance of long non-coding RNA MALAT1 in cancer[J]. Biochim Biophys Acta Rev Cancer, 2021, 1875: 188502. DOI: 10.1016/j.bbcan.2021.188502
    [26]
    Graves HC, Sensabaugh GF, Blake ET. Postcoital detection of a male-specific semen protein. Application to the investigation of rape[J]. N Engl J Med, 1985, 312: 338-343. DOI: 10.1056/NEJM198502073120603
    [27]
    Bolduc S, Lacombe L, Naud A, et al. Urinary PSA: a potential useful marker when serum PSA is between 2.5 ng/mL and 10 ng/mL[J]. Can Urol Assoc J, 2007, 1: 377-381. https://www.nature.com/articles/nrurol.2009.261
    [28]
    Pannek J, Rittenhouse HG, Evans CL, et al. Molecular forms of prostate-specific antigen and human kallikrein 2 (hK2) in urine are not clinically useful for early detection and staging of prostate cancer[J]. Urology, 1997, 50: 715-721. DOI: 10.1016/S0090-4295(97)00324-5
    [29]
    Occhipinti S, Mengozzi G, Oderda M, et al. Low Levels of Urinary PSA Better Identify Prostate Cancer Patients[J]. Cancers (Basel), 2021, 13: 3570. DOI: 10.3390/cancers13143570
    [30]
    Weir EG, Partin AW, Epstein JI. Correlation of serum prostate specific antigen and quantitative immunohistochemistry[J]. J Urol, 2000, 163: 1739-1742. DOI: 10.1016/S0022-5347(05)67532-5
    [31]
    Augustin H, Hammerer PG, Graefen M, et al. Characterisation of biomolecular profiles in primary high-grade prostate cancer treated by radical prostatectomy[J]. J Cancer Res Clin Oncol, 2003, 129: 662-668. DOI: 10.1007/s00432-003-0496-9
    [32]
    Hammarsten P, Josefsson A, Thysell E, et al. Immunoreactivity for prostate specific antigen and Ki67 differentiates subgroups of prostate cancer related to outcome[J]. Mod Pathol, 2019, 32: 1310-1319. DOI: 10.1038/s41379-019-0260-6
    [33]
    Yáñez-Mó M, Siljander PR, Andreu Z, et al. Biological properties of extracellular vesicles and their physiological functions[J]. J Extracell Vesicles, 2015, 4: 27066. DOI: 10.3402/jev.v4.27066
    [34]
    Théry C, Witwer KW, Aikawa E, et al. Minimal information for studies of extracellular vesicles 2018 (MISEV2018): a position statement of the International Society for Extra-cellular Vesicles and update of the MISEV2014 guidelines[J]. J Extracell Vesicles, 2018, 7: 1535750. DOI: 10.1080/20013078.2018.1535750
    [35]
    Zhang Y, Liu Y, Liu H, et al. Exosomes: biogenesis, biologic function and clinical potential[J]. Cell Biosci, 2019, 9: 19. DOI: 10.1186/s13578-019-0282-2
    [36]
    Boukouris S, Mathivanan S. Exosomes in bodily fluids are a highly stable resource of disease biomarkers[J]. Proteomics Clin Appl, 2015, 9: 358-367. https://www.sciencedirect.com/science/article/pii/S0163725817300347
    [37]
    Donovan MJ, Noerholm M, Bentink S, et al. A molecular signature of PCA3 and ERG exosomal RNA from non-DRE urine is predictive of initial prostate biopsy result[J]. Prostate Cancer Prostatic Dis, 2015, 18: 370-375. DOI: 10.1038/pcan.2015.40
    [38]
    Mckiernan J, Donovan MJ, O'neill V, et al. A Novel Urine Exosome Gene Expression Assay to Predict High-grade Prostate Cancer at Initial Biopsy[J]. JAMA Oncol, 2016, 2: 882-889. DOI: 10.1001/jamaoncol.2016.0097
    [39]
    Mckiernan J, Donovan MJ, Margolis E, et al. A Prospec-tive Adaptive Utility Trial to Validate Performance of a Novel Urine Exosome Gene Expression Assay to Predict High-grade Prostate Cancer in Patients with Prostate-specific Antigen 2-10 ng/ml at Initial Biopsy[J]. Eur Urol, 2018, 74: 731-738. https://www.sciencedirect.com/science/article/pii/S0302283818306043
    [40]
    Mckiernan J, Noerholm M, Tadigotla V, et al. A urine-based Exosomal gene expression test stratifies risk of high-grade prostate Cancer in men with prior negative prostate biopsy undergoing repeat biopsy[J]. BMC Urol, 2020, 20: 138. DOI: 10.1186/s12894-020-00712-4
    [41]
    Catalanotto C, Cogoni C, Zardo G. MicroRNA in Control of Gene Expression: An Overview of Nuclear Functions[J]. Int J Mol Sci, 2016, 17: 1712. DOI: 10.3390/ijms17101712
    [42]
    Bertoli G, Cava C, Castiglioni I. MicroRNAs as Biomarkers for Diagnosis, Prognosis and Theranostics in Prostate Cancer[J]. Int J Mol Sci, 2016, 17: 421. DOI: 10.3390/ijms17030421
    [43]
    Samsonov R, Shtam T, Burdakov V, et al. Lectin-induced agglutination method of urinary exosomes isolation followed by mi-RNA analysis: Application for prostate cancer diagnostic[J]. Prostate, 2016, 76: 68-79.
    [44]
    Foj L, Ferrer F, Serra M, et al. Exosomal and Non-Exosomal Urinary miRNAs in Prostate Cancer Detection and Prognosis[J]. Prostate, 2017, 77: 573-583.
    [45]
    Rodríguez M, Bajo-Santos C, Hessvik NP, et al. Identification of non-invasive miRNAs biomarkers for prostate cancer by deep sequencing analysis of urinary exosomes[J]. Mol Cancer, 2017, 16: 156. DOI: 10.1186/s12943-017-0726-4
    [46]
    Li J, Xu C, Lee HJ, et al. A genomic and epigenomic atlas of prostate cancer in Asian populations[J]. Nature, 2020, 580: 93-99.
    • Related Articles

  • Related Articles

    [1]WANG Jiali, LI Xiaohong, PEI Wenjing, LI Junxiang. Interpretation of Updates to the Modern Diagnosis of GERD: Lyon Consensus 2.0[J]. Medical Journal of Peking Union Medical College Hospital, 2025, 16(1): 125-132. DOI: 10.12290/xhyxzz.2024-0681
    [2]Rare Diseases Society of Chinese Research Hospital Association, National Rare Diseases Committee, Beijing Rare Disease Diagnosis, Treatment and Protection Society, Gitelman Syndrome Consensus Working Group. Expert Consensus for the Diagnosis and Treatment of Gitelman Syndrome in China (2021)[J]. Medical Journal of Peking Union Medical College Hospital, 2021, 12(6): 902-912. DOI: 10.12290/xhyxzz.2021-0555
    [3]WANG Yanqing, CHEN Yeye, HUANG Cheng, GUO Feng, ZHANG Ye, ZHANG Jieshi, GUO Chao, WANG Guige, LI Shanqing. Progress in the Diagnosis and Treatment of Pulmonary Carcinoids[J]. Medical Journal of Peking Union Medical College Hospital, 2021, 12(3): 366-372. DOI: 10.3969/j.issn.1674-9081.2020.00.006
    [4]Ming CUI, Ou WANG, Quan LIAO. Advances in Diagnosis and Surgical Treatment of Primary Hyperparathyroidism[J]. Medical Journal of Peking Union Medical College Hospital, 2020, 11(4): 395-401. DOI: 10.3969/j.issn.1674-9081.2020.04.007
    [5]Jian-hua DENG, Han-zhong LI. Diagnosis and Clinical Treatment of Primary Adrenal Lymphoma[J]. Medical Journal of Peking Union Medical College Hospital, 2020, 11(1): 91-95. DOI: 10.3969/j.issn.1674-9081.20170164
    [6]Ye-ye CHEN, Hong-sheng LIU, Shan-qing LI. Diagnosis and Treatment of Pulmonary Large-cell Neuroendocrine Carcinoma[J]. Medical Journal of Peking Union Medical College Hospital, 2019, 10(4): 393-397. DOI: 10.3969/j.issn.1674-9081.2019.04.016
    [7]Zhi-peng MAI, Wei-gang YAN, Zhi-gang JI, Han-zhong LI, Fu-quan ZHANG, Ke HU, Yu XIAO. Clinical Characteristics of Gleason Score 10 Prostate Cancer on Core Biopsy without Distant Metastases at Initial Diagnosis[J]. Medical Journal of Peking Union Medical College Hospital, 2016, 7(4): 275-279. DOI: 10.3969/j.issn.1674-9081.2016.04.007
    [8]Yu GU, Feng-zhi FENG, Yang XIANG, Xi-run WAN, Tong REN, Jun-jun YANG. Laparoscopy and/or Hysteroscopy in Differential Diagnosis and Treatment of Suspected Gestational Trophoblastic Neoplasia[J]. Medical Journal of Peking Union Medical College Hospital, 2016, 7(4): 253-258. DOI: 10.3969/j.issn.1674-9081.2016.04.003
    [9]Xue-min YAN, Hao SUN, Ai-ming YANG. Clinical Features and Diagnosis of Pancreatic Tuberculosis[J]. Medical Journal of Peking Union Medical College Hospital, 2015, 6(2): 119-123. DOI: 10.3969/j.issn.1674-9081.2015.02.009
    [10]Jun-chao GUO, Shu-jun XIA, Tai-ping ZHANG, Yu-pei ZHAO. Diagnosis and Surgical Treatment of Primary Abdominal Cocoon:Report of 12 Cases[J]. Medical Journal of Peking Union Medical College Hospital, 2013, 4(2): 165-168. DOI: 10.3969/j.issn.1674-9081.2013.02.017

  • Cited by

    Periodical cited type(2)

    1. 赵世豪，王俊涛，陈宽，王茜，王红玲，王文慧，梁宇聪，王祥麒. 国医大师唐祖宣治疗前列腺癌经验. 中医学报. 2025(02): 377-382 .
    2. 李宗霖，卢强，李远伟. 尿液代谢组学在前列腺癌中的应用研究进展. 中国现代医学杂志. 2024(08): 40-44 .

    Other cited types(0)

Catalog

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (1332) PDF downloads (159) Cited by(2)
    Related
    Links: National Health Commission of the People's Republic of China Chinese Academy of Medical Sciences(CAMS) AMLC Check CNKI Database CNKI Term Online Chinese General Practice
    Address：Room 302,Third Floor,Building 7, No. 1 Shuaifuyuan, Wangfujing, Dongcheng District, Beijing 100730, China
    Tel：010-69154261/4262
    E - mail：medj@pumch.cn mjpumch@126.com
    Copyright of website：Editorial Office of Medical Journal of Peking Union Medical College Hospital

    Supported by: Beijing Renhe Information Technology Co., Ltd.  Baidu Analytics

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return
    x Close Forever Close